The abstract is read at the publisher; the summary is JClub's.
CCR8xCD3 T cell-engaging bispecific antibody selectively depletes CCR8-expressing intratumoral regulatory T cells in preclinical mouse models, enabling tumor growth inhibition.
- Why it matters: Solid tumors often suppress antitumor immunity via tumor-infiltrating regulatory T cells, and conventional antibody depletion can be limited by scarce NK cells.
- What they did: The authors engineered a CCR8xCD3 TCB to engage CD3 and deplete CCR8+ T reg cells in vitro using human solid tumor samples, then tested tumor growth in multiple syngeneic mouse models alone or with anti-PD-L1.
- The result: In cynomolgus monkeys, the TCB was well tolerated without acute phase inflammation or cytokine release syndrome and produced effective, durable depletion of the CCR8-expressing T reg subset.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.